Cardiovascular disease Archives

News and Trends 1 Sep 2022

Brainomix awarded tender to deploy AI stroke imaging across whole of Hungary

Artificial intelligence (AI) stroke imaging will be deployed across centers in Hungary after Brainomix was awarded a national tender. The company was granted the tender for all stroke centers in the country as part of the National Institute for Health Development initiative to improve stroke care. Following a competitive process, the five-year program that was […]

September 1, 2022 - 4 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

Vaderis emerges from stealth to start HTT trial

Vaderis Therapeutics AG, a clinical stage biotech company focused on developing treatments for rare diseases associated with vascular malformations, has emerged from stealth. The company has also started its INSIGHT proof-of-concept clinical trial in patients suffering from hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome. About HHT HHT is a disorder where some blood […]

August 22, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jul 2022

Sanofi sells two portfolios of established products to Neuraxpharma

Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical company, Neuraxpharm Group. The company bought the portfolios from French healthcare company, Sanofi. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven […]

July 13, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Jul 2022

Novartis Pharmaceuticals UK launches health-tech investor partnership for cardiovascular care

Novartis Pharmaceuticals UK has launched the Novartis Biome UK Heart Health Catalyst 2022, in a world-first investor partnership with Medtronic ltd, RYSE Asset Management, and Chelsea and Westminster Hospital NHS Foundation Trust and its official charity CW+. The initiative aims to identify and implement solutions that empower patients to improve their heart health, and to […]

July 5, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 30 Jun 2022

Acticor Biotech gets patent for cardiovascular emergency treatment product

French company Acticor Biotech has announced the European Patent Office (EPO) has granted a new patent that provides protection for the use of Acticor’s product, glenzocimab in thrombotic diseases in Europe until 2036. The grant in Europe complements the ones already obtained in November 2020 in the U.S. and in November 2021 in Singapore, both […]

June 30, 2022 - 2 minutesmins - By Jim Cornall

cardiovascular disease heart attack forcefield therapeutics

News and Trends 25 Apr 2022

Forcefield Therapeutics Launched to Treat Heart Attacks with Protein Drugs

The startup Forcefield Therapeutics has been unveiled in the UK with €6M (£5.5M) backing from the investment firm Syncona. The mission is to develop the first drugs to safeguard heart muscle from damage during heart attacks. A sudden heart attack, also known as acute myocardial infarction, happens when the flow of blood to the heart […]

April 25, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 22 Feb 2022

Fast Stroke Treatments in the Works with TargED’s €39M Series A

Patients with sudden strokes and blood clotting conditions need faster and safer treatments. The Dutch company TargED Biopharmaceuticals has raised a €39M Series A round to fund the development of a fast-acting protein drug that could bridge this gap. Time is of the essence when treating acute ischemic stroke, a condition caused by a blood […]

February 22, 2022 - 5 minutesmins - By Jonathan Smith

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […]

April 21, 2021 - 5 minutesmins - By Victor Kotsev

In Depth 1 Mar 2021

How Are European Biotechs Tackling the Cardiovascular Disease Problem?

Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments on the market, there’s still a need for more effective treatments – can biotech companies provide the answer? We all know that frequent exercise, a […]

March 1, 2021 - 9 minutesmins - By Farhan Mitha

News and Trends 1 Feb 2020

Cardior Pharmaceuticals’ Heart Failure Drug Shows Curative Potential

German biotech company Cardior Pharmaceuticals’ candidate heart failure drug has the potential to stop the condition in its tracks, according to early studies in animal models. At present, treatments for heart failure, including ACE inhibitors, beta blockers, and diuretics, target the symptoms of the disease, such as high blood pressure, rather than the actual cause. […]

February 1, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 16 Dec 2019

Amarin’s Triglyceride-Lowering Drug Gets Second FDA Nod to Tackle Cardiovascular Disease

A treatment developed by the Irish company Amarin has become the first FDA-approved drug to lower the risk of strokes and heart attacks when combined with statins in patients with high levels of circulating fat molecules called triglycerides. To be eligible for Vascepa, patients must also either have established cardiovascular disease, or type 2 diabetes […]

December 16, 2019 - 2 minutesmins - By Jonathan Smith

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us